Order Today!

The old way of doing business in the life sciences industry — where one company develops, markets and sells a product — is gone for good. Today, licensing, joint ventures and acquisitions are increasingly the way businesses operate.

But what's the fair value of patents, early-stage products and licensing rights? The complicated and rapidly changing field of intellectual property (IP) valuation can overwhelm even seasoned veterans in the drug and device industry. Making just one bad decision in this arena can be financially devastating.

Introducing a new book to resolve the confusion: BVR’s Guide to Intellectual Property Valuation, Second Edition.

When it comes to valuing a company’s assets, bricks and mortar are the least of it. For most life sciences companies, the core value of a company’s assets lies in intellectual property — patents, copyrights, trademarks, secret processes.

Putting a fair market value on these one-of-a-kind intangibles can be very difficult, especially today. But it doesn’t have to be.

Announcing publication of
BVR's Guide to Intellectual Property Valuation, Second Edition

This all-new report from the nation’s leading business valuation analysts provides the framework to understand valuation of intellectual property and the tools to place values on your unique patents and processes.

Here’s just a taste of what you’ll discover:

• Case studies of IP valuation, including drug and device companies
• Overview of the principles, terms and techniques of IP valuation
• Three paths to valuation — cost, market and income — and how to integrate them
• Historical financial statements and how they affect valuations
• Assessing competitive advantages and assigning their value
• The risks of intellectual property infringement
• Conducting effective market analyses
• Topic-specific due diligence requirements for copyrights, patents, trademarks and trade secrets
• And much more!

Order today!

Author Michael Pellegrino of Pellegrino & Associates heads a team of engineers with finance experience and MBAs, well-versed in both technical complexities and marketplace and tax implications. Clients include Ascension Healthcare, GE, IBM, Sony, American Express, Lockheed Martin, Duke Energy, Liberty Mutual and Rolls-Royce North America, plus numerous small companies and startups.

BVR's Guide to Intellectual Property Valuation, Second Edition is “must” reading for CEOs and CFOs, as well as:

• Venture capitalists
• Investment bankers
• Auditors
• Legal counsel
• Business analysts

Don’t give away the store … and don’t overpay, either. With the economy heating up again, now is the time to get prepared — with BVR's Guide to Intellectual Property Valuation, Second Edition. Order your copies NOW.

Buy Now!

BVR's Guide to Intellectual Property Valuation, Second Edition in print format for $199. Order your copy.

Satisfaction Guaranteed
There's no risk when you purchase from FDAnews with our money-back guarantee. Not satisfied with your publication? Return the hard copy within 30 days (in resalable condition), and we will refund 100 percent of your purchase price (less shipping/handling).